Gut Microbiota-Mediated Alterations of Hippocampal CB1R Regulating the Diurnal Variation of Cognitive Impairment Induced by Hepatic Ischemia–Reperfusion Injury in Mice-Reference-Cited by-同舟云学术

Gut Microbiota-Mediated Alterations of Hippocampal CB1R Regulating the Diurnal Variation of Cognitive Impairment Induced by Hepatic Ischemia–Reperfusion Injury in Mice

Published:2024-06-02 Issue:8 Volume:49 Page:2165-2178
ISSN:0364-3190
Container-title:Neurochemical Research
language:en
Short-container-title:Neurochem Res

Author:

He Zhigang,Liu Yanbo,Li Zhen,Sun Tianning,Li Zhixiao,Liu Cheng,Xiang Hongbing^ORCID

Funder

National Natural Science Foundation of China

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s11064-024-04182-0.pdf

Reference33 articles.

1. Spies CD, Knaak C, Mertens M, Brockhaus WR, Shadenok A, Wiebach J, Kunzmann K, Feldheiser A, Pratschke J, Muller O, Kipping V, Fabian M, Abels W et al (2021) Physostigmine for prevention of postoperative delirium and long-term cognitive dysfunction in liver surgery: a double-blinded randomised controlled trial. Eur J Anaesthesiol 38(9):943–956. https://doi.org/10.1097/EJA.0000000000001456

2. He Z, Liu Y, Li Z, Sun T, Li Z, Manyande A, Xiang H, Xiong J (2023) Gut microbiota regulates circadian oscillation in hepatic ischemia-reperfusion injury-induced cognitive impairment by interfering with hippocampal lipid metabolism in mice. Hepatol Int. https://doi.org/10.1007/s12072-023-10509-w

3. Kim Y, Gautam S, Aseer KR, Kim J, Chandrasekaran P, Mazucanti CH, Ghosh P, O’Connell JF, Doyle ME, Appleton A, Lehrmann E, Liu QR, Egan JM (2020) Hepatocyte cannabinoid 1 receptor nullification alleviates toxin-induced liver damage via NF-kappaB signaling. Cell Death Dis 11(12):1044. https://doi.org/10.1038/s41419-020-03261-8

4. Hirsch S, Hinden L, Naim MB, Baraghithy S, Permyakova A, Azar S, Nasser T, Portnoy E, Agbaria M, Nemirovski A, Golomb G, Tam J (2023) Hepatic targeting of the centrally active cannabinoid 1 receptor (CB(1)R) blocker rimonabant via PLGA nanoparticles for treating fatty liver disease and diabetes. J Controll Release 353:254–269. https://doi.org/10.1016/j.jconrel.2022.11.040

5. Fonseca C, Ettcheto M, Bicker J, Fernandes MJ, Falcao A, Camins A, Fortuna A (2023) Under the umbrella of depression and Alzheimer’s disease physiopathology: can cannabinoids be a dual-pleiotropic therapy? Ageing Res Rev 90:101998. https://doi.org/10.1016/j.arr.2023.101998